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It is highly desirable to base decisions designed to im-
prove medical practice or organ allocation policies on
the analyses of the most recent data available. Yet
there is often a need to balance this desire with the
added value of evaluating long-term outcomes (e.g.
5-year mortality rates), which requires the use of data
from earlier years. This article explains the methods
used by the Scientific Registry of Transplant Recipients
in order to achieve these goals simultaneously.
The analysis of waiting list and transplant outcomes
depends strongly on statistical methods that can com-
bine data from different cohorts of patients that have
been followed for different lengths of time. A variety
of statistical methods have been designed to address
these goals, including the Kaplan-Meier estimator, Cox
regression models, and Poisson regression.
An in-depth description of the statistical methods used
for calculating waiting times associated with the vari-
ous types of organ transplants is provided. Risk of mor-
tality and graft failure, adjusted analyses, cohort selec-
tion, and the many complicating factors surrounding
the calculation of follow-up time for various outcomes
analyses are also examined.
Notes on Sources: The articles in this report are based on the
reference tables in the 2003 OPTN/SRTR Annual Report, which are
not included in this publication. The tables from the Annual Report
that serve as the basis for this article include the following: Tables
1.5, 1.6, 5.2, 5.3, 6.2, 6.3, 7.2, 7.3, 8.2, 8.3, 9.2, 9.3, 10.2, 10.3,
11.2, 11.3, 12.2, 12.3, 13.2, and 13.3. All of these tables are also
available online at http://www.ustransplant.org.
Funding: The Scientific Registry of Transplant Recipients (SRTR)
is funded by contract #231-00-0116 from the Health Resources
and Services Administration (HRSA). The views expressed herein
are those of the authors and not necessarily those of the US Gov-
ernment. This is a US Government-sponsored work. There are no
restrictions on its use.
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Introduction
This article describes the analytical approaches used in
various Scientific Registry of Transplant Recipients (SRTR)
analyses, including the 2003 OPTN/SRTR Annual Re-
port, the Center-Specific Reports (CSRs) published at
http://www.ustransplant.org, and analyses for committees
of the Organ Procurement and Transplantation Network
(OPTN) and Advisory Committee on Organ Transplanta-
tion (ACOT). Different questions require different analytical
methods, so a variety of methods are described here. Sub-
stantial attention is given to ensure that the analysis meth-
ods are appropriate to the quality, timeliness, and com-
pleteness of the data available.
SRTR analyses are widely used and quoted. Ensuring
timely, accurate, and relevant analysis results is an ongoing
challenge. Patients, physicians, policy makers, and admin-
istrators all use the results of SRTR analyses. The SRTR
attempts to address the individual needs of each type of
user, as well as to show appropriate new perspectives on
the issues relevant to these diverse audiences.
The data collected by transplant centers and organ procure-
ment organizations (OPOs) and submitted to the OPTN are
designed primarily to facilitate the efficient allocation of or-
gans to candidates and to allow limited evaluation of the
outcomes of this process. These data have become an
increasingly rich source of information about the practice
and outcomes of solid organ transplantation in the USA.
The SRTR has augmented the OPTN data by linking them
with other data sources; see ‘Transplant data: sources, col-
lection, and caveats’, a companion article in this report, for
details on these and other data sources (1).
The use of appropriate analysis methods is especially im-
portant for transplant data because of the complex longi-
tudinal nature of the data and the wide variation in medi-
cal practices, organs, candidates, and recipients present in
the data. All of the methods described here require careful
linking and accounting of the sequence of events for each
individual organ and patient. Many of the SRTR methods in-
volve the analysis of time to event data. Standard statistical
methods are used to aggregate data over time, including
calculation of average rates, Kaplan-Meier survival curves,
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and Cox models. These statistical methods are designed to
yield useful and interpretable results when data are com-
bined from groups of individuals with different character-
istics and lengths of follow-up, and with some incomplete
data.
Defining Salient Features of the Transplant
Process
When summarizing the transplantation process, many is-
sues arise that involve deciding what to count and how to
count them. The issues of availability of data are discussed
elsewhere in this report. Additionally, technical notes in the
2003 OPTN/SRTR Annual Report give detailed definitions
and methods for counting deceased donors, living donors,
organs recovered, waiting list registrations, transplant can-
didates, time spent on the waiting list, waiting list offers of
organs, transplant operations, organs transplanted, waiting
list deaths, graft failures, and post-transplant deaths (2). A
few of the most important distinctions are listed below.
A ‘donor’ is any person, living or deceased at the time of
organ removal, from whom an organ is procured with the
intention of transplantation, whether that organ is eventu-
ally transplanted or not. ‘Deceased donors’, also known
as cadaveric donors, are persons who have organs re-
moved for transplantation after death. ‘Living donors’ may
include individuals donating single kidneys, liver segments
or domino livers, lung lobes, or pancreas segments. A living
donor may also contribute a healthy heart when receiving
a simultaneous heart-lung transplant.
‘Transplanted organ’ counts may differ from the number of
‘transplants’. A kidney and pancreas transplanted from the
same donor to the same recipient count as one kidney-
pancreas transplant, but two transplanted organs; many
other multiple-organ combinations exist. A single liver may
be split into two segments for transplants in two different
recipients, leading to one organ recovered, two separately
coded organ dispositions, and two separate transplants.
A single ‘recipient’ may have more than one transplant
operation, such as a pancreas after kidney transplant, or
a retransplant following graft failure. Even among organs
from living donors, the number of transplants may be dif-
ferent from the number of living donors. For example, a
living donor might donate a kidney and pancreas segment,
or two living donors might each donate a lung lobe for one
transplant procedure.
‘A waiting list registration’ begins each time a patient is
placed on a waiting list at a transplant program. An indi-
vidual may have many registrations, occurring in sequence
at different centers or the same center, overlapping as a
‘multiple listing’ for the same organ at different centers, or
for more than one organ. ‘Candidate’ counts include all reg-
istrations, as well as recipients of living donor transplants,
who may not have been registered on any waiting list. An
individual, counted only once for multiple listings or trans-
plants, is referred to as a ‘patient’. In the Annual Report,
most waiting list tables reflect only one record per person,
even in the case of multiple listings.
Statistical Methods Overview
The analysis of time to event (wait-listing to transplant,
transplant to death, or transplant to graft failure) is compli-
cated by the fact that the reader often wants to know the
future prognosis for current groups of patients, while com-
plete outcomes data are available only for previous groups
of patients who have been followed for 1 or more years.
Because improvements in medical practices and changes
in organ allocation policy are occurring rapidly, it is useful
to use the most recent data available, but interest in long-
term outcomes necessitates using less recent data too.
For example, transplant failure rates during the fifth year
after transplant can only be estimated by using the expe-
rience of the cohort of patients who received a transplant
at least 5 years ago. Among those transplanted more than
5 years ago, some of the patients may have been lost to
follow-up, which complicates the calculation of cumulative
event rates. Another analytic goal is to improve the preci-
sion of estimates by including more subjects in a study, but
this also occurs at the expense of using less recent data.
For the reasons above, the analysis of waiting list and trans-
plant outcomes depends strongly on statistical methods
that can combine data from different cohorts of patients
that have been followed for different lengths of time. A va-
riety of statistical methods have been designed to address
these goals, including actuarial methods, the Kaplan-Meier
estimator, Cox regression, and Poisson regression. Many
of these were described in the 2002 Report on the State
of Transplantation (3).
Transplant waiting times
For each type of organ failure there is a shortage of or-
gans compared with the number of candidates who could
benefit from transplantation. A variety of methods of or-
gan allocation, each appropriate to the treatment options
available for that type of organ, are being developed to ad-
dress this shortage. Kidney transplants, which represented
slightly more than 46% of all deceased donor solid organ
transplants in 2002, are allocated primarily on the basis of
waiting time. Liver transplants are allocated primarily on
the basis of medical condition, as indicated by chronic vs.
acute organ failure and by the MELD score among chronic
liver failure patients. Allocation of hearts is based on medi-
cal condition and status. A recent proposal has been made
to change the lung allocation system from one based upon
waiting time to one based upon the net benefit of trans-
plantation, or the extra years of life gained by transplant dur-
ing some limited follow-up period (currently the proposal
is for the first year following transplantation) as well as
medical urgency. Allocation of organs according to the net
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benefit and urgency balances the value of avoiding immi-
nent death due to organ failure while also avoiding short-
term failed transplants. Evaluation of the expected net
years of life gained by transplant gives not only a criterion
for prioritizing candidates for organ allocation but also pro-
vides useful information to candidates about the relative
risks and benefits of transplantation.
Liver transplantation. In the face of these varied allocation
systems, the simple question, ‘How long is the wait for a
transplant?’ is no longer so simple to answer. For organs
that are allocated on the basis of medical condition or net
benefit, such as for liver transplantation, the medical condi-
tion of candidates is continually updated and candidates are
reprioritized according to their current condition. In some
regions of the country, candidates with very low risk of
death might never be allocated an organ unless and until
the time that their condition worsens.
Thus, instead of considering statistics about waiting times,
more relevant statistics for liver candidates may be found
in the answers to the following questions:
1 Among Status 1 candidates (acute liver failure), what
fraction get a transplant, what fraction die, and what
fraction recover?
2 Among chronic failure candidates, what is the rate of
transplantation per month during the time that their
MELD score has a particular value? What is the com-
peting risk that the patient dies during the same time?
Such statistics will allow the evaluation and comparison
of access to liver transplantation for the purposes of both
policy development and patient counseling. Similarly, for
each organ that is allocated on the basis of medical condi-
tion, it will be useful to report measures of transplantation
rates separately for different categories of medical con-
dition. Analogous methods can be used for candidates for
other organ transplants if allocation rules are changed from
a waiting-time basis to include death rates on the waiting
list as a criterion.
The use of MELD to allocate livers among chronic liver fail-
ure candidates began in February 2002, along with rules
for exceptions for candidates with other specific diseases,
such as liver cancer. The SRTR is developing relevant sum-
mary statistics and tables to summarize rates of liver trans-
plantation according to status and MELD, and expects
that the data will have stabilized sufficiently following the
change in allocation rules to allow such reporting in the
next cycle of Center-Specific Reports.
Kidney transplantation. For kidney transplants, which are
still allocated primarily according to waiting time, the SRTR
computes and reports several types of statistics, which
answer the following questions:
1 Among all registrants, what fraction received a trans-
plant within 1 year?
2 Among all registrants, how long did it take before 50%
of them had received a transplant?
3 What is the rate of transplantation among actively
listed candidates?
4 Among all recipients, how long did they wait on aver-
age?
Answers to questions 1 and 2 are the most relevant to
registrants because they give the prognosis for transplan-
tation accounting for all potential outcomes, including both
inactive time and death without transplant. Question 3 is
relevant for candidates who are actively listed and for evalu-
ation of the allocation process, which involves only actively
listed candidates. Question 4 is the least relevant to the
transplant community, but is the easiest to answer based
upon recent data. Questions 1, 2, and 4 can be answered
directly by evaluating outcomes in different groups of can-
didates, while question 3 involves a tabulation of person-
years in a calculation of rates.
For the purposes of ranking different regions or groups of
candidates, all of the questions above typically yield sim-
ilar results. The median time to transplant among recipi-
ents can be easily computed by counting recipients during
a recent interval of time. This statistic is useful for compar-
ing waiting times among regions or among transplant pro-
grams. However, the average waiting time among recipi-
ents is not useful for patient counseling, because it gives an
overly optimistic perspective compared with the prognosis
among registrants by not accounting for the possibility that
the patient might never receive an organ.
The outcomes for all wait-listed candidates are summa-
rized by the fraction who receive a transplant, die with-
out transplant, are removed for various reasons, are still
surviving after removal from the list, and are still on the
waiting list at various time points after wait-listing. Two
examples of such statistics are described here. Among
all registrants, the fraction transplanted (FT) is reported in
Table 5 of the CSRs at several time points after listing
(30 days, 1 year, 2 years, and 3 years) for each transplant
program (http://www.ustransplant.org). The FT is a simple
fraction of all wait-listed candidates who have received a
transplant, regardless of the program at which the trans-
plant is performed. The FT summarizes the time to trans-
plantation at any program among all registrants at a trans-
plant program.
The time to transplant (TTS) is the time since listing by
which 50% (or another stated fraction) of all wait-listed can-
didates receive a transplant. The TTS measures the rate of
transplantation at a particular program, so candidates who
transfer to another program’s waiting list or who are re-
moved for reasons of good health are dropped (censored)
at that time, using actuarial methods for the TTS outcome.
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Candidates who die or are removed from the list for rea-
sons of poor health are not censored and are counted as
never receiving a transplant in both the TTS and the FT
calculations. Note that the TTS would never be reached
for groups in which more than 50% of candidates die or
are removed for poor health, because these candidates are
counted as never receiving a transplant. The TTS calcula-
tion summarizes the time to transplantation at a transplant
program or within a group, taking into account the possi-
bility of not receiving an organ.
Different statistics are useful for the evaluation of organ al-
location policies for deceased donor organs. For example,
rates of transplantation among candidates on the waiting
list are useful for evaluating and comparing the impact of
allocation policies on different groups of candidates. Such
policies only affect candidates while they are active on the
waiting list. The Annual Report shows percentiles of wait-
ing time (WT) based on rates of deceased donor transplan-
tation among all candidates during the time from listing un-
til removal from the list, excluding inactive time. For such
calculations, time while inactive is excluded and candidates
are censored at removal from the list for any reason, includ-
ing death, poor health, good health, or living donor trans-
plant. The WT estimates the time that would result for a
hypothetical population with transplant rates identical to
those observed, if all candidates remained active on the
waiting list until transplant.
The various methods described above are all useful for
describing waiting times for transplantation and each is
appropriate for specific purposes. The choice of method
depends on the specific question or the purpose of the
question.
Mortality and Graft Failure Analysis
Actuarial methods use estimates of death rates to com-
pute the corresponding survival rates during successive
time intervals. The success rates for successive time in-
tervals are multiplied to yield the cumulative success rate
at the end of the final interval. Depending on the question
to be answered, these actuarial results are reported as ei-
ther the fraction that died, the fraction still surviving, or the
expected years of life through the end of the last interval.
Unadjusted (crude) post-transplant graft and patient sur-
vival outcomes are reported as cumulative ‘success’ rates.
These are calculated by Kaplan-Meier survival curves when
the analyses are based on data from a single cohort and
they are shown at various time points after transplant. Re-
sults from different cohorts are sometimes shown at var-
ious time points after transplant, as in the Adjusted and
Unadjusted Graft and Patient Survival Tables in the Annual
Report. However, since these results are from different
groups of patients, the outcomes are not consistent across
the years. For example, the 5-year survival for the 10-year
cohort is not reported and should not be assumed to be the
same as the 5-year survival that is reported for the 5-year
cohort. Several issues related to definitions for graft failure
and for dealing with incomplete mortality ascertainment
are discussed below.
Graft failure
What should be counted as a transplant failure? In order to
evaluate the lifetime of a transplanted organ, both retrans-
plant and death of the recipient are counted as transplant
failures, even if the death was unrelated to transplantation.
For kidney transplant recipients, return to dialysis is also re-
ported and counted as organ failure. In order to understand
the mechanisms that lead to transplant failure, however, it
is sometimes useful to count only failures of the trans-
planted organ itself, while not counting deaths from other
causes. In order to study such mechanisms, the actuarial
methods described previously can be used by censoring
the follow-up of an organ when a recipient dies without
organ failure.
Death rates and loss to follow-up
Generally, wait-listed registrants are not tracked for mor-
tality after they are removed from the waiting list. That
is, post-transplant mortality ascertainment stops when a
recipient is lost to follow-up. The incomplete follow-up
available in the data means that the actuarial methods de-
scribed above must censor patients when they are lost to
follow-up. If the failure rates after loss to follow-up are the
same as the failure rates among those still being followed,
then the actuarial method estimates are appropriate even
though some observations were censored. If recipients at
high risk for eventual failure are disproportionately lost to
follow-up before they fail, however, then the estimated fail-
ure rates will underestimate the overall failure rates. When
many subjects are lost to follow-up, it is important to know
whether subjects lost to follow-up were at high or low risk
for subsequent unreported events.
OPTN death ascertainment alone was used for computing
death rates on the waiting list, as reported in each organ-
specific section in the 2003 Annual Report. Such follow-up
stops when a candidate is removed from the waiting list,
because organ allocation is not affected by events after
removal from the waiting list. The death rate per patient-
year-at-risk method includes events and time only while on
the waiting list and is not affected by events after removal.
The resulting death outcomes, however, are difficult to in-
terpret because candidates are often removed from the
list if their health deteriorates to such a point that they are
no longer suitable for a transplant. (See the accompanying
article on data sources in this report (1) for a discussion of
postremoval deaths.) Thus, low death rates on a waiting
list are likely to reflect an effective screening process for
removing patients when their health deteriorates, but are
unlikely to reflect the survival prognosis for all wait-listed
candidates.
For the purposes of computing expected lifetimes on the
waiting list, the SRTR uses information on deaths from
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other data sources, such as the Social Security Death
Master File. This is especially important when comparing
pretransplant mortality (which includes time after removal
from the waiting list) to post-transplant mortality.
Adjusted Outcomes
Many of the analyses performed by the SRTR involve com-
parisons of outcomes. For example, the CSRs compare
mortality and graft failure rates at each transplant center
with national mortality and graft failure rates. In order to
make the comparisons more meaningful, they are adjusted
so that the outcomes at each facility are compared with
the outcomes that would be expected for the patient mix
at that facility. For example, the death rate might be high at
a facility that commonly performs transplants on high-risk
patients, but still lower than expected for such high-risk pa-
tients. The unadjusted higher mortality can be explained by
the large number of high-risk patients, but an unadjusted
mortality statistic would give no indication that the facil-
ity actually has better outcomes than expected for such
patients. In contrast, the adjusted comparison would cor-
rectly identify the facility as having good outcomes.
The SRTR adjustment method is called ‘indirect adjust-
ment’, which uses results from the various subgroups of
a standard population, often the national population, to
evaluate what would be expected for each patient among
those transplanted at a particular transplant center. The
subgroups generally are defined by patient age and other
patient characteristics, such as disease, that may affect
survival. We looked up the average event rate for the sub-
group to which each patient belongs. Based on that event
rate and how long each patient is followed, the expected
number of events for that patient is computed. The ex-
pected number is the product of the average event rate for
the subgroup that the patient is in, multiplied by the length
of follow-up for that patient. For example, a patient in a
subgroup with a national annual event rate of 0.10 (10%)
who is followed for 1.1 years would have 0.11 events ex-
pected during follow-up. These expected fractional counts
for all of the patients from each transplant center are added
together to yield the total expected events for the patients
at each center. The standardized ratio of the observed
to the expected counts is reported in the Center-Specific
Reports.
The SRTR uses another closely related adjustment
method, based on regression equations, to compare the
outcomes that would have resulted had the comparison
groups been otherwise equivalent. Regression equations
can be used to compute expected outcomes given a pa-
tient’s characteristics. The proportional hazards Cox regres-
sion model (4) is commonly used for adjusted analyses of
time to event data. Similar to the Kaplan-Meier estimates
described above, the Cox regression model can yield sur-
vival curve estimates for two or more groups of patients,
adjusted to show the comparison that would result if the
groups were equivalent with regard to particular factors,
such as age and diagnosis.
The results of a Cox model can be used to compare groups
or to show a trend among groups, based on the ratio of
event rates in each group, adjusted for other differences.
For example, an age- and diagnosis-adjusted relative risk
(RR) of 1.59 for post-transplant mortality rates for deceased
compared with living kidney donor recipients would indi-
cate that the death rate is 59% higher for recipients of
deceased kidney donor organs compared with recipients
of living kidney donor organs of the same age and diagno-
sis. An RR of 1.59 based on a 10% death rate would mean
that 15.9 instead of 10 deaths would be expected, if all
else were equal. An RR equal to 1.0 would indicate no dif-
ference in adjusted event rates between the comparison
groups.
The CSRs include comparisons of observed and expected
outcomes (mortality and graft failure), based on follow-
up of a cohort of recipients transplanted between 1 and
3.5 years prior to the report release for 1-month and 1-year
rates, and between 3.5 and 5.5 years prior for 3-year rates.
These cohorts are chosen to reflect the most recent time
period for which data were available. Survival percentages
at 1 month, 1 year, and 3 years are reported for each cen-
ter from both unadjusted (Kaplan-Meier) and adjusted (Cox)
survival models. The statistical comparison reported in the
p-value compares observed events with expected counts
from the Cox models rather than these survival percent-
ages. For example, if 14 events are observed in a facil-
ity during that time, while 9.2 would be expected given
the characteristics of the patients followed, then the event
rate for the group is 52% higher than expected, and the
p-value reported indicates the probability that the differ-
ence is due to chance (in the CSRs, differences with p <
0.05 are labeled as statistically significant).
Adjusted analyses, which are intended to make ‘all else
equal’ when comparing outcomes among different groups,
are used extensively by the SRTR in CSRs and reports to
committees. The choice of what to adjust for, or what to
make equal in the comparison groups, is an important one
that is under constant review by the SRTR and will differ
according to the specific purpose of the analysis. In or-
der to make meaningful adjustments, relevant data must
be available, complete, and accurate. The choice of fac-
tors used when adjusting center-specific outcomes for the
mix of characteristics at each center involves OPTN com-
mittees and SRTR analysts. The CSR documentation (avail-
able at http://www.ustransplant.org/programs-report.html)
includes detailed descriptions of the adjustment models
used in the CSRs.
Cohorts Chosen for Analyses
A cohort is a group of patients followed over time. Selec-
tion of the length of follow-up time for the cohort depends
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primarily on how much time must be allowed for the follow-
up to be sufficiently complete, whereas the number of pa-
tients in the cohort depends on statistical considerations,
such as event rates and power. In addition, the variability of
follow-up and the lags in reporting and transferring the data
affect the selection of the cohort. Several issues related to
the choice of a relevant cohort for analysis are summarized
below.
Allowing sufficient follow-up time
In the CSRs, we would like to be able to answer
the question, ‘What is the 1-year survival for patients
transplanted at this center in the past year?’ However, full
1-year outcomes are only known for those transplanted
at least 1 year previously. Based on OPTN policy, centers
are to submit follow-up reports within 60 days after the
transplant anniversary, with some time allowed for late re-
porting and for the data to flow through the OPTN to the
SRTR, and for additional data sources to be incorporated.
For the CSRs, the SRTR allows a 4-month reporting time
lag. Issues in choice of cohorts and follow-up patterns are
discussed in detail in ‘Transplant data: sources, collection,
and caveats’ (1).
Completeness of follow-up
There is considerable variation among transplant centers
in compliance with OPTN data submission requirements.
The actuarial method of measuring survival allows us to
use cases with incomplete follow-up, but as the level of
completion decreases, the potential for biased results in-
creases. For this reason, the SRTR computes a measure
of completeness of follow-up for the CSRs.
The ‘percent follow-up days reported by center’ reports the
percentage of days that were actually reported with follow-
up forms relative to the number of days that are targeted
for inclusion during the follow-up period. It is a measure
of the completeness of the data rather than a measure of
compliance. For patients who did not die before the end
of the period, the targeted number of days of follow-up
is the entire period, such as 365 days for 1-year follow-
up. For patients who die before the end of the period, the
number of targeted days of follow-up is the number of days
until death. A center can have 100% of expected forms
completed but less than 100% of expected days, because
some completed forms may not cover the entire follow-up
period. For example, when a center files a follow-up report,
it reports the patient’s last known status and the date of
that status. Thus a 1-year follow-up form may report the
patient’s status at the patient’s last visit, which was at 10
months. In this case, only 305 out of 365 days are actually
reported on a report that is submitted on time.
With the inclusion of Social Security Death Master File
(SSDMF) data, the number of days of follow-up covered by
any source is equal to the targeted number of days for all
patients, regardless of death, and is always equal to 100%.
However, because ascertainment of survival depends on
multiple sources of mortality information, the completion
of follow-up days reported by the center is still a valuable
measure for evaluating the validity of the data. Thus, even
after the incorporation of the SSDMF into the CSR follow-
up, the number of follow-up days is still reported in the
CSR and is based on center-reported data only.
The ‘percent of expected follow-up forms that have been
completed’ is another measure of completeness that is
reported to OPTN committees. When we are measuring
1-year follow-up, we expect a 1-year follow-up report or a
follow-up reporting death before 1 year. If a 1-year follow-
up form has not been completed, we accept a 2-year or
later report in lieu of the 1-year report, because the later
report confirms that the patient was alive at 1 year. This
measure reflects the transplant center’s compliance with
data reporting requirements.
Follow-up time
Post-transplant follow-up reports are completed at
6 months (for abdominal organs), at 1 year, and annually
thereafter. Variability in follow-up also affects the reliability
of the survival analysis. For instance, to analyze 2-year sur-
vival, we must allow time for the 2-year follow-up reports to
be filed for the latest transplants in the cohort; but in order
to analyze 2.5-year follow-up, the 3-year follow-up report is
needed. The OPTN requires that a follow-up form be filed
within 14 days of a post-transplant death, but unless the
transplant center still sees the patient regularly, the center
may not learn of a death until it prepares to complete the
next annual follow-up report. Analysis presented in ‘Trans-
plant data: sources, collection, and caveats’ shows that this
is often the case (1). The SRTR has established a protocol
for determining the end of follow-up to address these and
related problems, as described below.
The post-transplant death rate tables and the patient sur-
vival tables make use of multiple data sources to determine
the last known follow-up date to determine a censoring
time. Since the SRTR uses both the OPTN and SSDMF data
to find deaths, we expect to have nearly complete death
ascertainment for anyone receiving a transplant. During pe-
riods when we would expect to learn of a death from both
sources, if no death is reported then we assume that the
patient is alive.
Using multiple sources of death has implications for cen-
soring in mortality analyses. If only follow-up forms re-
turned to the OPTN were being used, censoring would
occur when the patient is reported as lost to follow-up, or
at the last follow-up form filed. After patients are lost to
follow-up in one data source, their time and events are fol-
lowed in other sources of mortality data. Therefore, the
patient is followed as long as we would expect report-
ing from both sources; constraints include the schedule
of follow-ups, which prompts OPTN members for follow-
up on transplant anniversaries, and lag in reporting to each
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source. The multiple-source follow-up or censoring date is
calculated in two steps. First a database cutoff date is set to
allow lag in reporting before the current database snapshot
date (August 1, 2003, for the 2003 Annual Report tables).
This lag time of 3–7 months depending on the analysis,
allows time for the reporting lags in data from both the
OPTN and the Social Security Administration. The multiple-
source censoring date is moved back even farther, to the
transplant anniversary (6 months, 1 year, 2 years, etc.) im-
mediately preceding this database cutoff date. It is through
this anniversary, when OPTN members are prompted
for follow-up forms, that we expect both sources to be
complete.
Events and follow-up time reported after this anniversary
are disregarded because they are probably a biased sam-
ple of outcomes. This is because events such as death
may be reported off schedule from the regular expected
follow-up forms. Patients who are alive will have follow-up
status reported only when forms are due at 6 months (for
nonthoracic organs), 1 year, 2 years, etc., after transplant.
When a patient dies, however, the center can report that
the patient died on an off-schedule follow-up form, creating
additional reporting on a (biased) sample of patients who
have died. Simply following patients until the last known
OPTN follow-up date will include extra time for patients
who die and have the follow-up form turned in early but
will not include this extra time for patients who are alive. To
eliminate this bias in reporting deaths, we follow patients
only until we expect to learn about all patients, both living
and deceased. Even when not using additional sources of
death ascertainment, it is important to consider this multi-
ple source censoring date in analyses for this reason. We
censor at the date of last expected follow-up, or the trans-
plant anniversary, for all patients. In some cases, this date
falls before reports of deaths filed to the OPTN by member
centers and means that certain deaths and follow-up time
will be excluded from analyses, but these exclusions are
made in the interest of obtaining an unbiased sample.
Statistical significance
In order to increase the accuracy of a reported statistic,
more patients can be included in an analysis by including
older cohorts of patients. While increasing the precision,
the inclusion of older cohorts carries the risk of yielding
results that no longer represent the current experience.
These opposing objectives must be balanced when choos-
ing the most recent cohort of patients for analysis. The
SRTR uses both p-values and confidence intervals, de-
scribed below, to help in the evaluation of the precision
of reported differences and statistics.
When making comparisons of outcomes, differences can
occur due to nonreplicable fluctuations resulting from
chance or random causes. It is important to distinguish
differences in outcomes that would probably recur upon
replication of the study from differences that arise due to
chance observations for a particular study group. Two ma-
jor tools are widely used to help assess the influence of
chance on a reported comparison. The ‘p-value’ is a statis-
tic that measures how likely it is that an observed or greater
difference might have occurred by chance alone when no
difference actually exists. The p-value is a probability, and
a p-value less than 0.05 (5%) is often used to establish
‘statistical significance’. The ‘confidence interval’ gives a
range in which we can be confident that the true (repli-
cable) difference is likely to be. For example, if 14 deaths
were observed in a cohort where 9.2 were expected for
similar patients, the RR is 1.52, which represents a 52%
higher mortality than expected. This difference, however,
is not significant (p-value >0.05) and the 95% confidence
interval indicates that the observed mortality could repre-
sent as high as 138% excess mortality or as low as 8%
reduced mortality compared with the expected.
Both the p-value and the confidence interval provide infor-
mation about the accuracy of a comparison. The p-value
depends on both the effect size and the sample size. Both
a larger effect size and a larger sample size tend to make
the p-value smaller. The clinical importance of a comparison
depends largely on the size of the estimated difference.
Comparing Treatment Alternatives
Many SRTR analyses are directed at the comparison of
outcomes for alternative treatments. Such comparisons
are complicated by the fact that patients often cross over
from one type of treatment to another, so outcomes for
pure treatment groups are not observed. Two types of
analyses are described here, one based upon data for two
observed treatment alternatives and another based upon
the projected outcomes that would result for pure treat-
ment groups using a competing risks methodology. Both
of these methodologies have recognized limitations inher-
ent in the nonexperimental nature of the observational data
available for analysis.
The death rates with and without transplant are used to
calculate the net benefit of transplant, in terms of extra
years of life because of transplantation. The post-transplant
death rates can be estimated based on the observed out-
comes among recipients. The death rates without trans-
plant, however, are more difficult to estimate because the
lifetime without transplant is not observed for those can-
didates whose lifetime without transplant is interrupted
by receiving a transplant. The death rates among those
without transplant can be estimated by actuarial compet-
ing risks analyses, which estimate death rates on the
waiting list censored at the time of transplant (5). This
methodology, however, has recognized limitations for or-
gans allocated on the basis of waiting list mortality, such as
livers. The death rates observed among those on the wait-
ing list do not represent the death rates that would re-
sult if the transplant option were removed, as impending
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deaths are selectively removed from the waiting list follow-
up group because of the priority given to high-risk patients.
This leads to overrepresentation of low-risk patients among
those remaining on the waiting list and underestimation of
the death rates that would result if the transplant option
were removed.
Two approaches have been used to compare outcomes
after an exceptional transplant relative to a standard trans-
plant. Examples of such analyses include comparison of
outcomes for split vs. whole livers, for expanded crite-
ria donor (ECD) vs. standard donor kidneys, for living
donor vs. deceased donor, and for dual- vs. single-kidney
transplants.
An as-treated analysis estimates death rates after receipt
of an exceptional organ and after receipt of a standard or-
gan. In addition, death rates without transplant can be esti-
mated using competing risks analysis of waiting list death
rates censored at the time of transplant with either type of
organ (5). All patients start in the waiting list group and can
cross over to either the standard or the exceptional trans-
plant groups. These three sets of death rates can then be
compared with respect to relative risk, cumulative survival
fractions, or expected lifetimes.
There are two major limitations to this as-treated methodol-
ogy. First, death rates on the waiting list are likely to be un-
derestimated, because high-risk patients are more likely to
receive a transplant and thus be removed from the wait-list
group than are low-risk patients. Second, the three treat-
ment groups do not represent the actual choice facing a
potential recipient of an exceptional organ, who has the
option of accepting the exceptional organ or continuing to
wait for a standard organ and the benefits of transplanta-
tion with a standard organ.
An alternative analysis addresses these two limitations
by comparing two treatment groups: exceptional therapy,
which is transplantation with an exceptional organ; and
standard therapy, which involves continuing to wait for and
possibly receive a standard organ. All patients start on the
waiting list in the standard therapy group and can cross
over to the exceptional therapy group.
The analysis of ECD kidneys demonstrates the differences
in interpretation of these two methods. The as-treated anal-
ysis shows that death rates following ECD transplantation
are lower than death rates among those remaining on the
waiting list but higher than death rates after transplanta-
tion with a standard organ. This suggests that receiving
an ECD organ is superior to remaining on the waiting list
but inferior to getting a standard donor organ. At the time
of offer of an expanded donor organ, however, the actual
choice being made is not a three-way choice, but only a
two-way choice between an ECD organ now vs. contin-
ued time on the waiting list with a possible standard donor
organ in the future. The two-group comparison shows very
little difference in mortality between the expanded therapy
option and the standard therapy option.
Organ allocation
The comparison of treatment outcomes with and with-
out transplant is an especially important consideration for
organ allocation. Death rates among candidates on the
waiting list with liver failure differ dramatically (over 100-
fold) between Status 1 (acute failure) candidates and
chronic liver failure candidates with MELD scores less than
10. With such disparities in death rates, it is of great value
to those at high risk of death to receive high priority so that
they will get a transplant before they die. At the same time,
it may be useful to identify candidates whose prognosis af-
ter transplantation is poor and give them lower priority for
transplantation. One approach toward balancing these two
goals, of avoiding pretransplant mortality and avoiding early
post-transplant mortality, is to rank candidates with regard
to the difference in projected lifetimes with and without
transplant, or the net extra years of life with transplant.
This gives a utilitarian measure of the benefit of transplan-
tation for each candidate in terms of extra years of life and
could be considered along with other allocation goals, such
as improving quality of life and assuring equity of access
to transplantation.
Statistical models for projected lifetimes with and without
transplant are used to calculate the net benefit, based on
the characteristics of each candidate and donor. Pre- and
post-transplant survival models are under constant devel-
opment for all organs, with special attention currently being
devoted to models for lung, liver, and heart, because major
changes in the allocation systems for these organs have
been recently made or proposed.
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